This week an FDA advisory panel reviewed the evidence on asthma medication and released recommendations about a class of inhaled medications that may be unsafe.  Their conclusions drew much media attention. The panel’s concern is the increasingly worrisome evidence about long-acting beta agonists (LABAs).  LABAs are a family of inhaled medications including Serevent and Foradil which are frequently used to treat asthma.  Studies have shown increased numbers of asthma exacerbations in patients t...